ORGANIC
LETTERS
2004
Vol. 6, No. 21
3655-3658
Synthesis of a C4-epi-C1−C6 Fragment
of FR901464 Using a Novel
Bromolactolization
Brian J. Albert and Kazunori Koide*
Department of Chemistry, UniVersity of Pittsburgh, 219 Parkman AVenue,
Pittsburgh, PennsylVania 15260
Received May 8, 2004 (Revised Manuscript Received August 18, 2004)
ABSTRACT
A synthesis of a C4-epi-C1
contains two of the three correct stereocenters found in the C1
developed a highly diastereoselective bromolactolization of a -alkenyl ketone.
−C6 fragment of the antitumor agent FR901464 is reported. The advanced intermediate prepared in this study
−C6 moiety of FR901464. For the preparation of this intermediate, we have
δ
Discoveries of antitumor agents with novel mechanisms
continue to be important in oncology and medicine.1 In the
quest for an anticancer agent with new modes of actions,
scientists at Fujisawa Pharmaceutical Co. isolated FR901464
(Figure 1) from the culture broth of Pseudomonas sp. No.
for biological studies, it is essential to develop a con-
vergent synthetic strategy for this natural product. In this
paper, we report the preparation of a highly functionalized
C4-epi-C1-C6 fragment of FR901464.4
Chemical syntheses of FR901464 have been accomplished
by two groups. The first total synthesis of FR901464 by the
Jacobsen group5 involves the application of a powerful
enantioselective hetero-Diels-Alder reaction.6 The second
total synthesis by the Kitahara group uses the chiral pool
for starting materials.7 Both groups further functionalized
the B-ring after the union of advanced intermediates, and
installation of the spiroepoxide in the late stages of the
syntheses proved problematic. To prepare various analogues
of FR901464 for biological studies, a convergent synthetic
approach using highly functionalized coupling intermediates
would be desirable.
Figure 1. Structure of FR901464.
2663.2,3 FR901464 increases the transcriptional activity of a
reporter gene driven by the SV40 promoter at 10 nM
concentration.3 This compound also exhibits cytotoxicity
against various human solid tumor cell lines at low nano-
molar concentrations.3 Despite these unique biological activi-
ties of FR901464, the mode of action of FR901464 is
poorly understood. To prepare various FR901464 analogues
(2) (a) Nakajima, H.; Sato, B.; Fujita, T.; Takase, S.; Terano, H.; Okuhara,
M. J. Antibiot. 1996, 49, 1196-1203. (b) Nakajima, H.; Takase, S.; Terano,
H.; Tanaka, H. J. Antibiot. 1997, 50, 96-99.
(3) Nakajima, H.; Hori, Y.; Terano, H.; Okuhara, M.; Manda, T.;
Matsumoto, S.; Shimomura, K. J. Antibiot. 1996, 49, 1204-1211.
(4) The numbering in this paper follows ref 2b.
(5) (a) Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. J. Am. Chem.
Soc. 2000, 122, 10482-10483. (b) Thompson, C. F.; Jamison, T. F.;
Jacobsen, E. N. J. Am. Chem. Soc. 2001, 123, 9974-9983.
(6) Dossetter, A. G.; Jamison, T. F.; Jacobsen, E. N. Angew. Chem., Int.
Ed. 1999, 38, 2398-2400.
(7) Horigome, M.; Motoyoshi, H.; Watanabe, H.; Kitahara, T. Tetrahe-
dron Lett. 2001, 42, 8207-8210.
(1) (a) Ferrante, K.; Winograd, B.; Canetta, R. Cancer Chemother.
Pharmacol. 1999, 43, S61-S68. Gibbs, J. B. Science 2000, 287, 1969-
1973. (b) Darnell, J. E., Jr. Nat. ReV. Cancer 2002, 2, 740-749. (c) Pompetti,
F.; Pilla, D.; Giancola, R. BioEssays 2003, 25, 104-107.
10.1021/ol049160w CCC: $27.50
© 2004 American Chemical Society
Published on Web 09/18/2004